Rowland Charles A Jr
CIK 0001383292 Name as filed on the most recent filing
Filed as Rowland Charles A Jr (19)
30 transaction lines · from 19 filings · filed 2008-11-05 to 2025-10-28 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Viking Therapeutics, Inc. 3 filings
- ISSUER Generation Bio Co. 6 filings
- ISSUER Nabriva Therapeutics plc 3 filings
- ISSUER Blueprint Medicines Corp 3 filings
- ISSUER Viropharma Inc 4 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
30 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-10-27 |
Viking Therapeutics, Inc. VKTX |
S, Open-market sale | 60,000 disposed | 35.57 | 2,134,278.00 | Form 4, filing 0001193125-25-254300 | |
| 2023-12-04 |
Generation Bio Co. GBIO |
P, Open-market purchase | 150,000 acquired | 1.50 | 225,000.00 | Form 4, filing 0001415889-23-015864 | |
| 2023-12-01 |
Generation Bio Co. GBIO |
P, Open-market purchase | 192,960 acquired | 1.31 | 252,777.60 | Form 4, filing 0001415889-23-015864 | |
| 2023-05-16 |
Viking Therapeutics, Inc. VKTX |
S, Open-market sale | 40,000 disposed | 25.00 | 1,000,000.00 | Form 4, filing 0001209191-23-030796 | |
| 2022-09-19 |
Generation Bio Co. GBIO |
P, Open-market purchase | 15,750 acquired | 5.26 | 82,845.00 | Form 4, filing 0001415889-22-009796 | |
| 2022-09-16 |
Generation Bio Co. GBIO |
P, Open-market purchase | 33,481 acquired | 5.48 | 183,475.88 | Form 4, filing 0001415889-22-009776 | |
| 2022-09-15 |
Generation Bio Co. GBIO |
P, Open-market purchase | 17,147 acquired | 5.41 | 92,765.27 | Form 4, filing 0001415889-22-009776 | |
| 2022-09-14 |
Generation Bio Co. GBIO |
P, Open-market purchase | 5,600 acquired | 5.30 | 29,652.00 | Form 4, filing 0001415889-22-009671 | |
| 2022-09-13 |
Generation Bio Co. GBIO |
P, Open-market purchase | 18,784 acquired | 5.20 | 97,751.94 | Form 4, filing 0001415889-22-009671 | |
| 2022-08-01 |
Nabriva Therapeutics plc NBRV |
S, Open-market sale | 8,496 disposed | 0.18 | 1,486.80 | Form 4, filing 0001104659-22-085790 | |
| 2021-08-02 |
Nabriva Therapeutics plc NBRV |
S, Open-market sale | 777 disposed | 1.20 | 932.40 | Form 4, filing 0001104659-21-100288 | |
| 2021-01-11 |
Generation Bio Co. GBIO |
P, Open-market purchase | 20,408 acquired | 24.50 | 499,996.00 | Form 4, filing 0001415889-21-000310 | |
| 2020-12-17 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 10,909 disposed | 117.82 | 1,285,298.38 | Form 4, filing 0001179110-20-012096 | |
| 2020-11-03 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 4,728 disposed | 99.10 | 468,544.80 | Form 4, filing 0001179110-20-010821 | |
| 2020-11-03 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 694 disposed | 95.97 | 66,603.18 | Form 4, filing 0001179110-20-010821 | |
| 2020-11-03 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 100 disposed | 100.48 | 10,048.00 | Form 4, filing 0001179110-20-010821 | |
| 2020-11-02 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 4,478 disposed | 99.11 | 443,814.58 | Form 4, filing 0001179110-20-010821 | |
| 2020-06-16 |
Generation Bio Co. GBIO |
P, Open-market purchase | 30,000 acquired | 19.00 | 570,000.00 | Form 4, filing 0000899243-20-017105 | |
| 2019-06-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 9,271 disposed | 94.83 | 879,168.93 | Form 4, filing 0001179110-19-008066 | |
| 2019-06-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 1,600 disposed | 96.08 | 153,728.00 | Form 4, filing 0001179110-19-008066 | |
| 2019-06-20 |
Blueprint Medicines Corp BPMC |
S, Open-market sale | 947 disposed | 96.69 | 91,565.43 | Form 4, filing 0001179110-19-008066 | |
| 2018-12-24 |
Nabriva Therapeutics plc NBRV |
P, Open-market purchase | 53,000 acquired | 1.31 | 69,430.00 | Form 4, filing 0001104659-18-074905 | |
| 2018-05-29 |
Viking Therapeutics, Inc. VKTX |
P, Open-market purchase | 30,000 acquired | 5.16 | 154,800.00 | Form 4, filing 0001209191-18-034490 | |
| 2012-03-01 |
Viropharma Inc VPHM |
S, Open-market sale | 70,000 disposed | 32.12 | 2,248,197.00 | Form 4, filing 0001127602-12-009534 | |
| 2012-03-01 |
Viropharma Inc VPHM |
S, Open-market sale | 12,750 disposed | 32.11 | 409,434.38 | Form 4, filing 0001127602-12-009534 | |
| 2011-03-14 |
Viropharma Inc VPHM |
S, Open-market sale | 25,000 disposed | 18.58 | 464,450.00 | Form 4, filing 0001127602-11-010253 | |
| 2011-03-14 |
Viropharma Inc VPHM |
S, Open-market sale | 10,000 disposed | 18.55 | 185,500.00 | Form 4, filing 0001127602-11-010253 | |
| 2009-02-26 |
Viropharma Inc VPHM |
P, Open-market purchase | 11,817 acquired | 4.78 | 56,485.26 | Form 4, filing 0001181431-09-011976 | |
| 2009-02-26 |
Viropharma Inc VPHM |
P, Open-market purchase | 4,183 acquired | 4.79 | 20,036.57 | Form 4, filing 0001181431-09-011976 | |
| 2008-11-03 |
Viropharma Inc VPHM |
P, Open-market purchase | 8,000 acquired | 12.77 | 102,160.00 | Form 4, filing 0001181431-08-059861 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 14
- Open-market sale 16
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Rowland Charles A Jr, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001383292
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6